We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Dr. Esteller Discusses: Open Access

Twitter Interview – #DrEstellerChatsOA – @tandfbiosci

Introducing Dr. Manel Esteller, Editor-in-Chief, Epigenetics

Dr. Manel Esteller graduated in Medicine from the University of Barcelona, where he also obtained his Ph.D. degree specialising in cancer molecular genetics. He is the Director of the Josep Carreras Leukaemia Research Institute (IJC), Chairman of Genetics in the School of Medicine of the University of Barcelona, and an ICREA Research Professor, as well as the Editor-in-Chief of Epigenetics.

His current research is devoted to the establishment of the epigenome and epitranscriptome maps of normal and transformed cells, the study of the interactions between epigenetic modifications and non-coding RNAs, and the development of new epigenetic drugs for cancer therapy.

Author of more than 600 original publications in peer-reviewed scientific journals, 24 of them categorized as “Highly Cited Paper”, Dr. Esteller is considered among the Top 0.01% of World Scientists based on Impact by both the Stanford University (METRICS) and the Web of Science Group-Clarivate Analytics. In 2021 he was been elected as Member of the Academia Europaea and of the European Academy of Sciences.

Twitter interview: #DrEstellerChatsOA

From 2023, Epigenetics is converting to a fully open access journal (having operated under a hybrid model previously). We recently met with Dr. Esteller via Twitter (@Tandfbiosci) to discuss this move, the journal, and why open access research is so important to the field.

We had a great discussion examining the role of open access, tips for authors wanting to publish in the journal and more.

You can still check out the Q&A on Twitter using #DrEstellerChatsOA, or see Dr. Esteller’s answers to our questions below!

You can still join the conversation:

Q&A with Dr. Esteller

Q1. Firstly, can you tell me a bit about the journal, Epigenetics?

““Epigenetics” was the first journal focused in this biological and medical field with the goal to publish the best research in the area.”

Q2. What are the current challenges facing researchers in this field?

“The definition of Epigenetics is always difficult but we welcome articles in DNA methylation, histone modifications, RNA regulation and chromatin.”

Q3. Why was it decided to convert Epigenetics to a fully open access journal?

“How science is communicated is changing a lot, and a fully open access journal will allow access to a new generation of scientists and labs around the world.”

Q4. What impact does open access have on the field of epigenetics research, why is it so important?

“It can enhance a lot the impact of epigenetics in other fields such as genetics and transcription, we are in a multiomics era!”

Q5. What are the benefits for the author of publishing their research openly? Why do you think authors should publish their research openly in Epigenetics?

“The outreach of the article would be greater with a speedy publication time.”

Q6. What do you look for in an open access article submission to the journal? What topics are you most interested to cover in the journal?

“We would love exciting stories dealing of how epigenetics shape the activity of normal and pathological cells and tissues!”

Q7. Have you had any particularly interesting open access articles published recently?

“Two examples: the effect of human histone mutations in neurodevelopmental disorders and CRISPR/dCas9 mediated editing of the epigenome.”

Q8. What do you think the open research future looks like for your field?

“Open research is here to stay. We live in a global world where knowledge has to be shared.”

Q9. What gets you excited about open research?

“The capacity to disseminate and exchange results in a free manner.”

Q10. What advice would you give someone considering publishing their research openly in Epigenetics?

“Please do it. Your research will be highly followed and will make a greater impression in the worldwide community.”

Thinking of submitting your research?

Epigenetics is particularly interested in receiving manuscripts on:

  • DNA methylation

  • Nucleosome positing and modification

  • Gene silencing

  • Imprinting

  • Chromatin remodeling

  • Non-coding RNA

  • Dosage compensation

  • Epigenetic therapy and diagnostics

  • Cancer epigenetics

  • Neuroepigenetics

Why publish open access?

  • Increase the visibility and readership of your research by publishing in a fully open access journal.

  • Make an impact beyond the academy by making your article accessible to anyone, anywhere (including readers in industry and even policy-makers).

  • Benefit from format-free submission, saving you more time for your research.

  • Freely share your work with no restrictions or paywall.

  • Retain ownership of your research through our unrestrictive publishing agreements.

  • Discounts and waivers for researchers in developing countries are available. The journal will also consider requests for discretionary APC waivers. Find out if your institution or country has an open access agreement to publish with us.

Find the latest tweets from @tandfbiosci

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.